TRACON ends development of envafolimab, exploring strategic options
2024-07-01
Zhanna Hapanovich TRACON Pharmaceuticals (OTC:TCON) said it is discontinuing development of its oncology drug candidate envafolimab after a key clinical trial failed to meet its primary endpoint and will concentrate instead on exploring strategic alternatives for the company. TRACON said that the study, ENVASARC, failed to meet its primary endpointContinue Reading